Our Sponsors
Medical Research COuncil (MRC)UKRI are again pleased to support the GLOW’24 conference Rising to the challenge: Women's and Newborn's Health in the context of Global Crises.
MRC–UKRI, funds research is at the forefront of science to prevent illness, develop therapies and improve human health. As part of MRC’s strategic delivery plan (22-25) vision is to fund an impactful MRC portfolio in promoting healthy ageing throughout life and reduce the burden of mental and physical illness. Women’s health research in its broadest sense forms part of the MRC portfolio. This ranges from underpinning molecular biology to population health. MRC's cancer portfolio explores sex-specific cancer types including ovarian cancer; MRC’s ageing portfolio, research efforts extend to understanding the impact of ageing on women's health, covering areas such as menopause, bone health, particularly osteoarthritis which disproportionately affects women, cardiovascular issues, and neurodegenerative diseases, including dementia. Population health research also covers the potential challenges and requirements for female patients. MRC is actively engaged in global initiatives, ensuring that women's health is considered in addressing health disparities and promoting equitable healthcare on a global scale, Infectious diseases including , nutrition deficits, gender based violence, Education, prenatal and postnatal care. The MRC spend on research relating to women’s health the last 5 years with an average spend of just under £25M p.a. |
|
|
Gedeon RichterGedeon Richter have a presence in over 100 countries worldwide and have been working to change lives for the better since 1901. We are one of the few companies in the world to offer a comprehensive portfolio for women; our R&D team continue to innovate and extend our gynaecological, fertility and osteoporosis portfolio, aiming to address women’s healthcare needs in these areas. Our ambition is to help women achieve theirs.
|
Roche DiagnosticsAt Roche Diagnostics we believe time is precious and we are dedicated to providing diagnostic tests and services that give us all more time with the people we love
We are proud to be the UK’s leading provider of in vitro diagnostic tests1. We also work in partnership with the NHS and other healthcare providers to try and ensure every patient journey begins with an early and accurate diagnosis, and to play our part in the delivery of efficient and effective healthcare for everyone. In the UK, in 2020, more than 820 million Roche diagnostic tests were used by clinicians to confirm, rule out or manage health conditions including cancer, heart disease, diabetes, COVID-19, hepatitis, human papillomavirus (HPV) and many others2. Despite half of the population being female, gender inequality remains a key issue and women often feel overlooked. At Roche we are passionate about improving the health and wellbeing of women through every stage of their lives. Our ambition is to produce, and enable equitable access to, innovative, sustainable and patient-centered diagnostic solutions and to play a key role in shaping the future of women’s health through long-term initiatives and partnerships. Through Roche’s direct business activities and employee spending, we contribute £1.26 billion to the UK economy and provide 21,260 jobs3. We also invested more than £400 million in UK Research and Development (R&D) in 20214. For more information please visit - website: www.roche.co.uk - Twitter: @RocheDiaUK - LinkedIn:@Roche Diagnostics UK and Ireland
|
|
|
Sibel HealthSibel Health is an award-winning health technology company with a mission to deliver Better Health Data for All®. Based in Chicago with an international office in Seoul, the company's FDA-cleared ANNE® platform includes advanced wearable sensors, AI-enabled data analytics, and an integrated mobile software and cloud platform. Sibel has partnerships with some of the most respected healthcare organizations worldwide with a specific focus on maternal neonatal monitoring.
|
THe Faculty of Sexual and Reproductive HealthcareThe Faculty of Sexual and Reproductive Healthcare (FSRH) is the leader in the field of sexual and reproductive healthcare, and we are the voice for 14,000 professionals working in this area. As a multi-disciplinary professional membership organisation, we set clinical guidance and standards, provide training and lifelong education, and champion safe and effective sexual and reproductive healthcare across the life course for all.
|
|
